GT Biopharma, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of immuno-oncology products based on its proprietary immune cell fusion protein Tri-specific Killer Engager (TriKE) technology platform hookers. The company develops several candidate immuno-oncology products, including GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in a phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory acute myeloid leukemia / relapsing or advanced. systemic mastocytosis and other hematopoietic neoplasms CD33 +; GTB-C3550, a continuation of its main TriKE candidates, GTB-3550; GTB-4550, a recombinant fusion protein conjugate of tri-specific single-stranded variable fragments (scFv) for the treatment of PD-L1+ solid tumor cancers; and GTB-5550, a tri-specific single-chain scFv recombinant fusion protein conjugate for the treatment of B7H3+ solid tumor cancers. GT Biopharma, Inc. has a joint development partnership agreement with Altor BioScience Corporation for the clinical development of a TriKE 161533 fusion protein for cancer therapies; a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapy for the treatment of coronavirus infection. The company was previously known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is headquartered in Beverly Hills, California.
How to Buy GT Biopharma Stock (GTBP) Tutorial Explained
Are you looking for how to buy GT Biopharma (GTBP) shares on Nasdaq safely and through a regulated broker? Are you interested in being able to monetize your earnings per month and make profits on the stock market? In this tutorial I am going to show you how you can invest in DEGIRO , a regulated investment broker with minimum commissions, and how you will be able to acquire shares of GT Biopharma, Inc. (GTBP) (GTBP) quickly and easily.
The tutorial is intuitive :
- To begin, we will register a debit account, an interface where we will buy shares of GT Biopharma, Inc. (GTBP), (GTBP).
- Now we will add capital and thus make our 1st investment.
- When we finally have the funds we have to look for the GT Biopharma company by its Ticker, GTBP.
- To finish, we will only go on to adjust the number of shares that we want to buy, the price and type of order.
The checklist may have been too essential for you, so let’s see the whole step by step with images:
How to sign up for degiro
The first step is to register with DEGIRO through this link :
It will ask us for an email, a username and a password to have access, and then we will have to continue from the link that they have sent us by mail.
Soon Degiro will request important information from us in order to approve our identification card . We will need to have your passport number, DNI or driving license, your mobile phone and the number of the bank account that we are going to apply to carry out our first deposit. If you don’t understand how this format is, you can check this simple tutorial for use that we elaborated in Educacep .
Once our account is approved we can put money from the Enter / Withdraw section. We can make a transfer that will take more or less 1 to 2 days, or we can make the deposit instantly with Sofort, a totally secure and very reliable payment gateway.
How to buy GT Biopharma (GTBP) shares through DEGIRO
In the time that we have the money we will be able to buy our 1st share. You can go to the place order button on the top right or select the turn search engine and paste the ticker. In the following screenshot you will find that I have put the Amazon Ticker but in your case you should put (GTBP), the GT Biopharma ticker. As we are talking about an action, we will see that the related tickers are listed and there we will look at finding GT Biopharma. The most important thing is that the ticker, the name of the company and the market in which it is listed coincide. Amazon is listed on NASDAQ (NDQ) and in your case GT Biopharma, Inc. (GTBP) is listed on Nasdaq. This step is very important so make no mistake.
At the time of placing the order, we are going to pay special attention to what I am going to explain to you now . We can place a limit or market order. Imagine that you want to get a share of GT Biopharma at 17.09, but its price today is more prominent. With a limit order we will place the value at which we plan to make the purchase and until there are no shares for sale at this value, the purchase operation of the share will not be executed. With a market order, you will buy the number of shares that we have indicated at the true selling price, which would be very close to the current trading price.
In any circumstance it is very important that you look at the type of alignment: permanent or day . To give an example, in Spain, the stock market price is from tomorrow until 1:00 p.m., and in the USA it coincides with the afternoon schedule in Spain. If an order is permanent, it will continue until it can be executed, but if you select the “of the day” option, at the end of the day, if it is not executed, it will be removed from your Activity – Processing Orders section.
I would like this detailed article to be useful to you to buy shares in GT Biopharma.
|Name||Title||Payment||exercised||Year of birth|
|Mr. Anthony J. Cataldo||Chairman, CEO and President||362k||N/A||1952|
|Mr. Michael D. Handelman||Chief Financial Officer and Accountant||528.25k||N/A||1959|
|Gregory I. Berk, MD||Medical director||2.5k||N/A||1958|
|Mr. Martin Schroeder||Head of Technology||N/A||N/A||1953|
|Dr. Jeffrey S. Miller MD||Consultant Scientific Director and Scientific Advisor||N/A||N/A||N/A|
Recent GT Biopharma events:
Recent Events July 09, 2020 Filed in Full 8-K: Entering into Substantial Definitive Agreement, Unrecorded Sale of Equity Securities June 19, 2020 Filed in Full 8-K: Entering into Material Definitive Agreement, Creation of Financial Obligation May 15, 2020 Full Filed 10-Q: Quarterly Report March 27, 2020 Full Filed 10-K: Annual Report Nov. 14, 2020 2019 Full Filed 10-Q: Quarterly Report